Esperion Therapeutics Stock Price and Value Analysis

Esperion Therapeutics (NasdaqGM:ESPR) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Esperion Therapeutics to reach your target.

Target type

ESPR Free Cash Flow Trend

Free Cash Flow trendline for ESPR
Free Cash Flow trendline for Esperion Therapeutics

Hmm, we can't give any reliable projection for Esperion Therapeutics's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

AdvantagesDisadvantagesNeutral
None.
  • This stock looks overpriced.
  • This company is less known than others.
  • This company has wild ups and downs.
  • This company is not making money.
  • This company pays no dividend.

Inside the ESPR Numbers

ESPR Price
(Esperion Therapeutics stock price per share)
$0.00
[?] PE Ratio versus Sector 100% lower than other Healthcare stocks
[?] PE Ratio versus Industry 100% lower than other Drug Manufacturers - General stocks
[?] Free Cash Flow Jitter 83%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Net income was negative in all 15 fiscal years from 2011 to 2025, so no ratio of operating cash flow to net income is shown. Operating cash flow totaled -$1,202 million over those years, against net income of -$1,606 million.

In 2025, net income was -$22.7 million and operating cash flow was -$13.1 million, so no ratio is shown for that year.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2011 -10.8 -9.1 0 n/a
2012 -11.7 -10.8 0 n/a
2013 -26.1 -18.1 0 n/a
2014 -36.4 -32 0.9 n/a
2015 -49.8 -38.2 0.3 n/a
2016 -75 -47.7 0.1 n/a
2017 -167 -131 0 n/a
2018 -202 -149 0.2 n/a
2019 -97.2 -70.3 1 n/a
2020 -144 -85.2 0.9 n/a
2021 -269 -264 not reported n/a
2022 -234 -175 not reported n/a
2023 -209 -135 not reported n/a
2024 -51.7 -23.7 0.3 n/a
2025 -22.7 -13.1 not reported n/a

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $148 million in 2019 and $403 million in 2025, a compound annual growth rate of 18.1% over 6 years.

Revenue rose 21.3% from 2024 to 2025.

Our estimated free cash flow was -$13.2 million in 2025, a negative margin of 3.3% of revenue, meaning the estimate was below zero. In 2019 the estimated margin was negative 47.6%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2019 148 -70.6 -47.6%
2020 228 -85.6 -37.6%
2021 78.4 -264 -336.8%
2022 75.5 -175 -232.2%
2023 116 -136 -116.8%
2024 332 -23.9 -7.2%
2025 403 -13.2 -3.3%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $168 million against total liabilities of $768 million, or 21.9% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 164.8% of total assets in 2025, compared with 665.7% in 2012, a decrease of 500.9 percentage points.

Stockholders equity was negative in 2025, at -$302 million, which means the company's liabilities and other claims on its assets exceeded the assets themselves. Companies that return cash through large buybacks can show negative equity for that reason alone, but it also leaves no book value cushion for shareholders.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2012 7.3 6.5 48.7 -41.4
2013 78.3 56.5 4.2 74.1
2014 143 85 9.7 134
2015 296 77.3 8.3 287
2016 245 38.2 16.6 229
2017 278 34.5 33.1 245
2018 143 37 64.3 79.1
2019 214 166 194 19.9
2020 353 305 449 -96.1
2021 382 209 579 -197
2022 248 125 572 -324
2023 206 82.2 661 -455
2024 344 145 733 -389
2025 466 168 768 -302

Price Versus Our Estimated Value

None of the 15 fiscal years we have for Esperion Therapeutics under its current SEC filer shows positive free cash flow.

Year-to-year variability in free cash flow is volatile, measured at 83%.

We do not estimate a fair value for Esperion Therapeutics while its free cash flow growth is not positive, so there is no value comparison here.

No dividend yield is recorded for Esperion Therapeutics in our data.

Our value investing guide explains how to test these numbers against the filings themselves.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 100% below the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 100% below the average for stocks in the Drug Manufacturers - General industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Drug Manufacturers - General industry, the ones closest in market capitalization to Esperion Therapeutics, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Esperion Therapeutics (ESPR) - - - - -
Abbott Laboratories (ABT) 178,390 38.4 2.4% 1.9% 49% above
Alkermes plc (ALKS) 7,552 - - 1.5% 315% above
Amphastar Pharmaceuticals (AMPH) 1,205 13.0 - 0.9% 98% above
ANI Pharmaceuticals (ANIP) 1,558 13.9 - - 188% above
Bristol-Myers Squibb Company (BMY) 120,192 13.0 4.3% 1.2% 85% above
Collegium Pharmaceutical (COLL) 768 22.7 - - 155% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1434868.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow was negative in 15 of the 15 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • We have no value estimate for this stock, so no price comparison is made.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: ESPR annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in ESPR

Does Esperion Therapeutics have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: ESPR

This example shows how we apply the Trendshare checklist to ESPR: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 0.00
    • Market cap: —
    • EPS: —
  2. Step 2 — Valuation checks

    • P/E: —
    • FCF yield: —
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.